Research Library — Compounded Enforcement Data | Reta Compare
25 research articles in Compounded Enforcement Data. Page 1 of 1.
Articles
- FDA Warning Letters in the GLP-1 Compounding Space 2024–2026
- Eli Lilly Litigation Tracker: Defendants and Status 2026
- 503A vs 503B Pharmacy Counts
- Tirzepatide Shortage Timeline: Key Dates
- Compounded GLP-1 Adverse Event Reports
- Bulks List Inclusion: 503A and 503B Status of GLP Peptides
- Outsourcing Facilities Association Litigation Outcomes
- State-Level Peptide Bills 2024–2025
- RFK Jr. and HHS Peptide Policy Statements
- BPC-157 and TB-500 Regulatory Status 2026
- FDA Inspection Activity at GLP-Compounding Pharmacies
- Compounded GLP-1 Patient Disruption Estimates
- Telehealth Platform Regulatory Settlements 2024–2026
- FDA Bulks List Process Statistics
- Eli Lilly Marketing Claim Disputes
- Compounded Semaglutide Volume Decline 2025–2026
- FDA Import Alerts Affecting Peptide API
- Compounded GLP-1 Insurance Coverage Reality
- Peptide Litigation Discovery Timelines 2026
- Compounded Retatrutide: A Different Legal Picture
- FDA Guidance Document Activity 2025–2026
- Compounding Quality Failure Rates
- Telehealth Platform Subscriber Churn 2025–2026
- Cross-Border Compounded GLP Activity
- Compounded Enforcement: Aggregate Costs to Industry